Results of clinical trials for locally advanced and metastatic nonsmall-cell lung cancer

Sakkaraiappan Ramalingam, Chandra Belani

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Chemotherapy in nonsmall-cell lung cancer (NSCLC) is not just a reality but has resulted in important improvements in quality of life and survival for patients with locally advanced and metastatic NSCLC. For patients with stage IV NSCLC, platinum-based 2-drug combinations are superior to single-agent therapy and have a superior therapeutic index than 3-drug combinations. Concurrent chemoradiation has become the standard of care for patients with locally advanced NSCLC. The addition of consolidation chemotherapy following definitive chemoradiation appears to improve median survival. The era of molecularly targeted therapies for NSCLC is here. Early results with some of the targeted agents studied for the treatment of NSCLC have generated a great deal of excitement. In this article, we review the results of recent clinical trials in locally advanced and metastatic NSCLC.

Original languageEnglish (US)
Pages (from-to)438-447
Number of pages10
JournalSeminars in Thoracic and Cardiovascular Surgery
Volume15
Issue number4
DOIs
StatePublished - Jan 1 2003

Fingerprint

Non-Small Cell Lung Carcinoma
Clinical Trials
Drug Combinations
Consolidation Chemotherapy
Survival
Therapeutics
Standard of Care
Platinum
Quality of Life
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{4fd9c90569774da7adb67fe0148072ec,
title = "Results of clinical trials for locally advanced and metastatic nonsmall-cell lung cancer",
abstract = "Chemotherapy in nonsmall-cell lung cancer (NSCLC) is not just a reality but has resulted in important improvements in quality of life and survival for patients with locally advanced and metastatic NSCLC. For patients with stage IV NSCLC, platinum-based 2-drug combinations are superior to single-agent therapy and have a superior therapeutic index than 3-drug combinations. Concurrent chemoradiation has become the standard of care for patients with locally advanced NSCLC. The addition of consolidation chemotherapy following definitive chemoradiation appears to improve median survival. The era of molecularly targeted therapies for NSCLC is here. Early results with some of the targeted agents studied for the treatment of NSCLC have generated a great deal of excitement. In this article, we review the results of recent clinical trials in locally advanced and metastatic NSCLC.",
author = "Sakkaraiappan Ramalingam and Chandra Belani",
year = "2003",
month = "1",
day = "1",
doi = "10.1053/S1043-0679(03)00097-2",
language = "English (US)",
volume = "15",
pages = "438--447",
journal = "Seminars in Thoracic and Cardiovascular Surgery",
issn = "1043-0679",
publisher = "W.B. Saunders Ltd",
number = "4",

}

Results of clinical trials for locally advanced and metastatic nonsmall-cell lung cancer. / Ramalingam, Sakkaraiappan; Belani, Chandra.

In: Seminars in Thoracic and Cardiovascular Surgery, Vol. 15, No. 4, 01.01.2003, p. 438-447.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Results of clinical trials for locally advanced and metastatic nonsmall-cell lung cancer

AU - Ramalingam, Sakkaraiappan

AU - Belani, Chandra

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Chemotherapy in nonsmall-cell lung cancer (NSCLC) is not just a reality but has resulted in important improvements in quality of life and survival for patients with locally advanced and metastatic NSCLC. For patients with stage IV NSCLC, platinum-based 2-drug combinations are superior to single-agent therapy and have a superior therapeutic index than 3-drug combinations. Concurrent chemoradiation has become the standard of care for patients with locally advanced NSCLC. The addition of consolidation chemotherapy following definitive chemoradiation appears to improve median survival. The era of molecularly targeted therapies for NSCLC is here. Early results with some of the targeted agents studied for the treatment of NSCLC have generated a great deal of excitement. In this article, we review the results of recent clinical trials in locally advanced and metastatic NSCLC.

AB - Chemotherapy in nonsmall-cell lung cancer (NSCLC) is not just a reality but has resulted in important improvements in quality of life and survival for patients with locally advanced and metastatic NSCLC. For patients with stage IV NSCLC, platinum-based 2-drug combinations are superior to single-agent therapy and have a superior therapeutic index than 3-drug combinations. Concurrent chemoradiation has become the standard of care for patients with locally advanced NSCLC. The addition of consolidation chemotherapy following definitive chemoradiation appears to improve median survival. The era of molecularly targeted therapies for NSCLC is here. Early results with some of the targeted agents studied for the treatment of NSCLC have generated a great deal of excitement. In this article, we review the results of recent clinical trials in locally advanced and metastatic NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=0346505546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346505546&partnerID=8YFLogxK

U2 - 10.1053/S1043-0679(03)00097-2

DO - 10.1053/S1043-0679(03)00097-2

M3 - Review article

C2 - 14710386

AN - SCOPUS:0346505546

VL - 15

SP - 438

EP - 447

JO - Seminars in Thoracic and Cardiovascular Surgery

JF - Seminars in Thoracic and Cardiovascular Surgery

SN - 1043-0679

IS - 4

ER -